Overall verdict
Sell
3.2/10
1-year performance
-4.57%
Score breakdown
Down 4.6% over 1 year, 25% of the 52-week range.
Strongest: Financial strength 5.8/10. Weakest: Shareholder return 0.0/10.
11 analysts, target +2.7% vs the price.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Samuel Reich
Founded
2014
Employees
86
Revenue / employee
0 USD
Next earnings
March 8, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC1.53%
- Bank of New York Mellon Corp0.14%
- Rest of the register98.33%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
5.15 USD
52-week low
2.44 USD
1-year performance
-4.57%
Declining
Year-to-date performance
-17.20%
Declining
Drawdown
-39.22%
Major drawdown
Position in the 52-week range
25% of range
ROIC -34.5%, ROE -35.4%.
Net margin
—
Sector -207.84%|S&P 13.40%
Gross margin
—
Return on equity (ROE)
-35.38%
Negative
Sector -57.88%|S&P 17.06%
Return on invested capital (ROIC)
-34.50%
Negative
Free cash flow margin (FCF)
—
Revenue to net income
Growth
0.0/10Revenue down 62.4% over 1 year.
Revenue (trailing 12 months)
0 USD
Revenue growth (1y)
-62.40%
Declining
Revenue growth (3y)
-100.00%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.8x|S&P 23.6x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 15.0x|S&P 15.5x
PEG
—
Sector -0.08|S&P 0.91
Market cap
282M USD
Financial strength
5.8/10Cash covers 2115.7% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-47.00%
Net cash
Cash
104M USD
Cash / market cap
36.90%
Very solid
Cash / total debt
2115.68%
Net cash
Interest coverage
-367.4x
Stretched
Net debt
-99.1M USD
Equity
211M USD
Closed daily candles, 2 years
Last close on November 10, 2026: 3.07 USD
- MM202.96
- MM503.16
- MM2003.65
- RSI 1450.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-2.59%
200-day average slope, 3 months
-3.25%
50-day average slope, 1 month
-10.03%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
5.17 % per day
Volatility change
+49.59%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.96 (8) | -1.13 (3) | 0 (8) | -92 (2) | -90 (9) |
| 2027 | -0.72 (10) | -0.94 (5) | 0 (7) | -111 (2) | -104 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 9, 2026.
Same sub-industry: 772 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LRMR | 5.6 | N/A | 284M USD | Not meaningful (loss) | — | — | -135.7 % | 0.8x | -55.0 % | -21.3 % | ||
| 2 | FYB | 4.8 | 3.2 | 290M USD | Not meaningful (loss) | -41.0 % | -36.2 % | -6.2 % | -4.2x | -2.2 % | -30.3 % | ||
| 3 | ALERS | 4.3 | 4.4 | 287M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 7.1 % | ||
| 4 | NWBO | 3.5 | 4.0 | 290M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.2 % | -32.6 % | ||
| 5 | SABS | 3.2 | 0.9 | 282M USD | Not meaningful (loss) | — | -62.4 % | -34.5 % | — | -20.8 % | -4.6 % | ||
| 6 | 688426 | 2.9 | 3.2 | 299M USD | Not meaningful (loss) | -35.4 % | 24.1 % | -6.0 % | — | -0.5 % | -35.6 % | ||
| 7 | LCTX | 2.7 | 1.5 | 281M USD | Not meaningful (loss) | -246.6 % | -61.3 % | -57.7 % | 1.9x | -8.7 % | -43.3 % | ||
| 8 | A174900 | 2.4 | 2.6 | 298M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.0 % | -10.7 % | ||
| 9 | CRNA | 1.8 | 0.4 | 298M USD | Not meaningful (loss) | — | — | -25.6 % | 8.3x | -1.8 % | 900.5 % |
